These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8513798)

  • 21. Mutation of serine 90 to glutamic acid mimics phosphorylation of bovine prolactin.
    Maciejewski PM; Peterson FC; Anderson PJ; Brooks CL
    J Biol Chem; 1995 Nov; 270(46):27661-5. PubMed ID: 7499231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The N-terminus of human prolactin modulates its biological properties.
    Bernichtein S; Jomain JB; Kelly PA; Goffin V
    Mol Cell Endocrinol; 2003 Oct; 208(1-2):11-21. PubMed ID: 14580717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical modification of ovine prolactin with N-acetylimidazole.
    Cymes GD; Iglesias MM; Wolfenstein-Todel C
    Int J Pept Protein Res; 1993 Jul; 42(1):33-8. PubMed ID: 8370641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human placental growth hormone variant is mitogenic for rat lymphoma Nb2 cells.
    Nickel BE; Kardami E; Cattini PA
    Endocrinology; 1990 Feb; 126(2):971-6. PubMed ID: 2298178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor-mediated mitogenic action of prolactin in a rat lymphoma cell line.
    Shiu RP; Elsholtz HP; Tanaka T; Friesen HG; Gout PW; Beer CT; Noble RL
    Endocrinology; 1983 Jul; 113(1):159-65. PubMed ID: 6305632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptor.
    Svensson LA; Bondensgaard K; Nørskov-Lauritsen L; Christensen L; Becker P; Andersen MD; Maltesen MJ; Rand KD; Breinholt J
    J Biol Chem; 2008 Jul; 283(27):19085-94. PubMed ID: 18467331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism for ordered receptor binding by human prolactin.
    Sivaprasad U; Canfield JM; Brooks CL
    Biochemistry; 2004 Nov; 43(43):13755-65. PubMed ID: 15504038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elephant prolactin: isolation and characterization.
    Li CH; Chung D; Bewley TA; Cabrera CM
    Int J Pept Protein Res; 1987 Apr; 29(4):472-7. PubMed ID: 3596899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociation of Janus kinase 2 and signal transducer and activator of transcription 5 activation after treatment of Nb2 cells with a molecular mimic of phosphorylated prolactin.
    Coss D; Kuo CB; Yang L; Ingleton P; Luben R; Walker AM
    Endocrinology; 1999 Nov; 140(11):5087-94. PubMed ID: 10537136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioactive recombinant methionyl bovine prolactin: structure-function studies using site-specific mutagenesis.
    Luck DN; Gout PW; Beer CT; Smith M
    Mol Endocrinol; 1989 May; 3(5):822-31. PubMed ID: 2666850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of residues outside the two binding sites that are critical for activation of the lactogenic activity of human growth hormone.
    Duda KM; Brooks CL
    J Biol Chem; 2003 Jun; 278(25):22734-9. PubMed ID: 12682073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovine prolactin and human growth hormone derivatives. Specific modification of their alpha-amino groups.
    Caridad JJ; Nowicki C; Santomé JA; Wolfenstein-Todel C
    Int J Pept Protein Res; 1988 Jun; 31(6):509-13. PubMed ID: 3410636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solution structure of human prolactin.
    Teilum K; Hoch JC; Goffin V; Kinet S; Martial JA; Kragelund BB
    J Mol Biol; 2005 Aug; 351(4):810-23. PubMed ID: 16045928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tubulin secondary structure analysis, limited proteolysis sites, and homology to FtsZ.
    de Pereda JM; Leynadier D; Evangelio JA; Chacón P; Andreu JM
    Biochemistry; 1996 Nov; 35(45):14203-15. PubMed ID: 8916905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological activity and immunological reactivity of human prolactin mutants.
    Rhee HK; Sun Z; Kim SS; Goffin V; Martial JA; Dannies PS
    Endocrinology; 1995 Nov; 136(11):4990-5. PubMed ID: 7588233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Receptor binding and conformational properties of bovine and ovine prolactins after chemical modification of the two tryptophan residues.
    Kochman H; Garnier J; Kochman K
    Biochim Biophys Acta; 1979 May; 578(1):125-34. PubMed ID: 222337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocytosis and degradation of ovine prolactin by Nb2 lymphoma cells: characterization and effects of agents known to alter prolactin-induced mitogenesis.
    Augustine EC; Kensinger RS
    Endocrinology; 1990 Jul; 127(1):200-10. PubMed ID: 2113865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of lactogenic activities of ovine prolactin and human growth hormone (hGH) by a novel form of a modified recombinant hGH.
    Gertler A; Shamay A; Cohen N; Ashkenazi A; Friesen HG; Levanon A; Gorecki M; Aviv H; Hadary D; Vogel T
    Endocrinology; 1986 Feb; 118(2):720-6. PubMed ID: 2417826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.
    Bernichtein S; Kinet S; Jeay S; Llovera M; Madern D; Martial JA; Kelly PA; Goffin V
    Endocrinology; 2001 Sep; 142(9):3950-63. PubMed ID: 11517174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiestrogen inhibition of prolactin-induced growth of the Nb2 rat lymphoma cell line.
    Biswas R; Vonderhaar BK
    Cancer Res; 1989 Nov; 49(22):6295-9. PubMed ID: 2804977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.